Результаты поиска

Candida auris in a Tertiary Care Hospital in Oman: A Five-Year Study of Epidemiology, Clinical Characteristics, and Antifungal Susceptibility.

Background Candida auris (C. auris) is an emerging multidrug-resistant pathogen known for causing persistent colonization, invasive infectio … diate voriconazole susceptibility (44.8%), and preserved echinocandin activity (caspofungin, 96.6%; micafungin, 100%) and flucytosine activity (80.0%). Conclusions The findings demonstrate that C. auris imposes a considerable burden on hospitalized patients, with marked morbidity in those who develop invasive disease, particularly candidemia. The organism's …

Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal Diseases.

BackgroundSargramostim (yeast-derived, glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) augments innate and adaptive immune responses and accelerates hematopoietic recovery of chemotherapy-induced neutropenia. However, considerably less is known about its efficacy as adjunctive immunotherapy against invasive fungal diseases (IFDs).MethodsThe clinical courses of 15 patients with pediatric malignancies and IFDs treated adjunctively with sargramostim at a single institution were analyzed in a retrospective cohort review. Further, a systematic review of

Совпадение в полном тексте источника
… , liver, spleen, kidneys, and brain while receiving micafungin treatment | Treated with LAmB and sargramostim. … rhu GM-CSF and micafungin in voriconazole-resistant infection, with no further metastatic nodules observed. …

Clinical features and outcomes of four patients with invasive fungal sinusitis.

OBJECTIVE: The frequency of invasive fungal sinusitis (IFS) has increased in recent years with the use of steroids, onset of diabetes mellitus, and the administration of antibacterial agents. We report on the clinical features and outcomes of four patients with IFS involving the cavernous sinus and orbit. Prognostic factors facilitating an early diagnosis are described, and the usefulness of combination therapy involving systemic administration of antifungal agents and surgical intervention is discussed. METHODS: We treated four patients with IFS between March 2003 and November 2007 at Ehime

[Clinical characteristics of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus infected children].

Objective: To analyze the clinical characteristics of Pneumocystis jirovecii pneumonia (PJP) in non-human immunodeficiency virus (HIV) infec … ed with trimethoprim-sulfamethoxazole monotherapy, 19 cases (32%) received combination therapy with micafungin, and 7 cases (12%) received combination therapy with clindamycin. Fifty-three cases (90%) required varying degrees of respiratory support. Concurrent glucocorticoid therapy was administered in 70% (41/59) of cases at anti-PJP treatment initiation. F …

Eradication of invasive mucormycosis--effectiveness of the Echinocandin FK463.

BACKGROUND: Invasive rhinocerebral mucormycosis is a rare and often fatal opportunistic fungal infection. It is encountered in immunocompromised hosts exemplified by those with diabetes, human immunodeficiency viruses and particularly haematologic malignancies typically after high-dose chemotherapy and stem cell transplantation. In contrast to the more usual outcome with rapid progression and death. We now describe a successful eradication attributable to the use of a newly available antifungal agent. SETTING: Haematology department and bone marrow transplantation unit. MATERIAL AND METHOD:

Смертельная диспропорция фусариоза во время вводного терапия для взрослой острой лимфоболической лейкемии у пациента с приорной множественной миеломой.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Antimicrobial prophylaxis consisted of acyclovir 400 mg q12h, ciprofloxacin 500 mg q12h, and micafungin 50 mg daily from day 1. Micafungin was preferred to avoid azole-vincristine interactions, and additive hepatotoxicity during asparaginase-containing induction. … Micafungin was discontinued while intravenous voriconazole (loading dose 6 mg/kg q12h on day 1, followed by 4 mg/kg q12h) together with liposomal amphotericin B (5 mg/kg/day) was initiated on day 21, in line with current recommendations. 3 , 4 Despite PegAsp-related hepatic dysfunction, full doses were …

Evaluation of resistance patterns and bioremoval efficiency of hydrocarbons and heavy metals by the mycobiome of petroleum refining wastewater in Jazan with assessment of molecular typing and cytotoxicity of Scedosporium apiospermum JAZ-20.

Jazan Industrial Economic City (JIEC) is located on the Red Sea coast in the province of Jazan, southwest of Saudi Arabia anchors diverse he … nazole, posaconazole, isavuconazole and ketoconazole), echinocandin (anidulafungin, caspofungin and micafungin) and polyene (amphotericin B) drugs proved the prevalence of antibiotic resistance among the mycobiome of refinery industry in Saudi Arabia is relatively low. The fungal isolate under isolation code JAZ-20 showed the highest bioremoval efficiency ag …

Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).

The oestrogenised vagina is colonised by Candida species in at least 20% of women; in late pregnancy and in immunosuppressed patients, this … e treatment with high-dose fluconazole, oral posaconazole and, more recently, echinocandins such as micafungin are under discussion; echinocandins are very expensive, are not approved for this indication and are not supported by clinical evidence of their efficacy. In cases of vulvovaginal candidosis, resistance to C. albicans does not play a significant rol …

Antifungal Management in Patients with Hematological Malignancies: From Primary Prophylaxis to Empirical and Diagnosis-Driven Treatment

Invasive fungal diseases (IFDs) remain a significant cause of morbidity and mortality among patients with hematological malignancies, especially those undergoing intensive chemotherapy or hematopoietic stem cell transplantation (HSCT). This text provides a comprehensive risk-adapted framework for antifungal prophylaxis, stratifying patients into high-, intermediate-, and low-risk categories. Mold-active prophylaxis, primarily with posaconazole, is recommended for high-risk patients such as those with acute myeloid leukemia during remission induction or those with grade III-IV graft-versus-host

Совпадение в полном тексте источника
… This finding supports the conclusion that micafungin does not offer superior mold protection over fluconazole in this population [ 22 ]. … N Engl J Med 2007 356 4 348 359 10.1056/NEJMoa061094 17251531 14 Deveci B Yücel OK Kublashvili G Iltar U Ataş Ü Toptas T Turhan Ö Saba R Micafungin prophylaxis in patients with acute lymphoblastic leukemia. …

Navigating Trichosporon Asahii Infections in Pediatric Leukemia: First Reported Case in Central and Eastern Europe Case Report and Literature Review.

Invasive fungal infections pose significant challenges in the management of immunocompromised patients, particularly those undergoing treatment for hematologic malignancies. Trichosporon asahii is a rare but severe cause of invasive trichosporonosis, associated with mortality rates. Effective management is complicated by its resistance to echinocandins and reduced susceptibility to polyenes, necessitating azole-based therapy. This paper aims to illustrate the diagnostic challenges associated with Trichosporon infections, analyze the complexities of treatment, review and synthesize known risk f

Совпадение в полном тексте источника
… One of them was treated with caspofungin, and six, including our patient, received micafungin. For the remaining eight cases, the antifungal agent used was unspecified. … Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis . 2006;42(6):753–757. doi: 10.1086/500323 35. Arendrup MC, Boekhout T, Akova M, et al. …

Association of HSV-1 and Reduced Oral Bacteriota Diversity with Chemotherapy-Induced Oral Mucositis in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Oral mucositis (OM) is a common complication of chemotherapy and remains a significant unmet need. The aim of this study was to investigate the role of oral bacteriota and HSV-1 in OM. Forty-six patients admitted for autologous hematopoietic stem cell transplantation were longitudinally evaluated for OM, Candida, HSV-1, and leukocyte count, and buccal mucosal bacterial samples were obtained during their admission period. The bacterial communities collected at the baseline and post-chemotherapy, chosen from the time with the highest severity, were analyzed by sequencing the 16S rRNA gene. Twent

Совпадение в полном тексте источника
… Despite the uniform prophylactic administration of micafungin and the use of nystatin gargle, colonization with Candida spp. was observed in 18 patients, which may be attributed to anti-fungal resistance in Candida [ 19 ]. … First, ciprofloxacin, chlorhexidine, micafungin, and nystatin were uniformly used, and their role in the chemotherapy-accompanied dysbiosis of buccal mucosal bacteriota cannot be clarified. …

Mutations in immunodeficiency-related genes may increase the risk of infection after CAR-T-cell therapy: a report of two cases.

BackgroundChimeric antigen receptor T-cell therapy (CAR-T) has yielded unprecedented efficacy in B-cell malignancies. With the increasing use of CAR-T-cell therapy, infection has become one of the major concerns after CAR-T-cell infusion. Some patients even develop refractory or recurrent infections, posing challenges in treatment, prophylactic, and monitoring strategies. However, the mechanisms underlying the development of these infections were not clear.Case presentationWe report two cases of infection after CAR-T-cell therapy. Patient 1, diagnosed with multiple myeloma, received anti-B-cel

Совпадение в полном тексте источника
… Empirical antibacterial drugs were given immediately, but the antifungal agent was not changed since we had just downgraded our prophylactic antifungal strategy from micafungin to oral voriconazole. … From Day 56, the antifungal agent was changed back to micafungin since the patient had no more complaints (Fig. 1 A). To explore the potential reason for persistent refractory fungal infection, whole-exome sequencing was performed. …

[Expert consensus on diagnosis and treatment of severe COVID-19 associated pulmonary aspergillosis and mucormycosis].

The incidence and mortality of COVID-19 associated pulmonary aspergillosis (CAPA) are high in critically ill patients. Although COVID-19 ass … e used as a salvage therapy strategy. Triazole or amphotericin B in combination with caspofungin or micafungin is recommended; whereas amphotericin B in combination with triazole is not recommended. For CAPM patients with extensive lesions, rapid progression or poor general condition, a combination of amphotericin B liposome with isavuconazole or posaconazol …

A review on clinical cases of rare mold infections and their antifungal treatment strategies.

In recent years, with the growing population of immunocompromised individuals, infections caused by rare environmental molds have become increasingly prevalent and clinically significant. Due to frequent misdiagnosis and difficult clinical management, the overall disease burden of such infections poses a major challenge in clinical practice. This article aims to fill the knowledge gap by reviewing cases of rare mold infections from January 2020 to February 2026, analyzing the susceptible populations, identification techniques, antifungal susceptibility testing, and antifungal treatment strateg

Совпадение в полном тексте источника
… This isolate was susceptible to amphotericin B, terbinafine, and voriconazole, resistant to micafungin, and showed intermediate susceptibility to itraconazole. … After treatment with posaconazole first and then micafungin, the inflammatory condition in the patient's lungs improved significantly ( Figure 4II ) ( Pechacek et al., 2023 ). …

The prevalence of antifungal agents administration in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective study.

BackgroundInvasive fungal infections (IFIs) are chief infectious complications in patients undergoing hematopoietic stem cell transplantation (HSCT). However, the diagnosis of fungal infections is difficult, and often empiric treatment initiates. Since there is no data available on the prevalence of antifungal drugs administration in allogeneic HSCT recipients in Iran, we decided to conduct this study.MethodsThis study was a retrospective review of records of patients who received allogeneic HSCT in the Hematology-Oncology, Bone Marrow Transplantation center at Shariati Hospital in Tehran, bet

Совпадение в полном тексте источника
… This was probably due to the unavailability of micafungin, and anidulafungin and restricted availability of caspogungin in Iran. Additionally, the cost of the latter drug was not covered by the medication insurance systems at the time of the study. … Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther. 2009;31(5):1105–15. doi: 10.1016/j.clinthera.2009.05.011. 11. …

Amphotericin B Colloidal Dispersion Is Effective and Safe for the Treatment of Invasive Aspergillosis in Chinese Patients with Hematologic Disease: A Multicenter, Prospective, Observational, Real-World Study.

PURPOSE: Invasive aspergillosis (IA) causes significant morbidity and mortality in hematologic patients. This study aimed to evaluate the efficacy and safety profile of amphotericin B colloidal dispersion (ABCD) for IA in this high-risk population. PATIENTS AND METHODS: This multicenter, prospective, observational study enrolled hematologic patients with IA. Eligible patients received ABCD for up to 28 days or until investigator-assessed clinical response or intolerance. The primary outcome was clinical response rate, and the secondary outcome was 28-day all-cause mortality following the last

Совпадение в полном тексте источника
… 43 (66.15) Serum GM positive/tested 4/36 (11.11) Plasma GM positive/tested 3/6 (50.00) BALF GM positive/tested 0/1 (0.00) ECOG score, n (%) 0–2 61 (93.85) 3–4 4 (6.15) Previous antifungal prevention or treatment, n (%) 51 (78.46) Voriconazole 29 (44.62) Posaconazole 16 (24.62) Caspofungin 12 (18.46) Micafungin … positive/tested | 4/36 (11.11) Plasma GM positive/tested | 3/6 (50.00) BALF GM positive/tested | 0/1 (0.00) ECOG score, n (%) | 0–2 | 61 (93.85) 3–4 | 4 (6.15) Previous antifungal prevention or treatment, n (%) | 51 (78.46) Voriconazole | 29 (44.62) Posaconazole | 16 (24.62) Caspofungin | 12 (18.46) Micafungin …

Population-Based Active Surveillance for Culture-Confirmed Candidemia - 10 Sites, United States, 2017-2021.

PROBLEM/CONDITION: Candidemia, a bloodstream infection caused by Candida spp., is a common cause of health care-associated bloodstream infec … intensive care unit stay before the index date increased from 38.3% to 44.9%. Echinocandins (e.g., micafungin) were used as treatment in 49.8% of cases, and azoles were used in 47.7%. The all-cause in-hospital mortality rate was 32.6%; this increased from 26.8% in 2019 to 36.1% in 2021. Overall, Candida albicans accounted for 37.1% of cases, followed by Can …

Infections in Recipients of Hematopoietic Stem Cell Transplants

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… , voriconazole | Systemic infection: <5% colonization: 30% Aspergillus and other molds 78 , 79 , 86 , 227 , 228 , 242 | 1-4 | HEPA air filtration Itraconazole, voriconazole, posaconazole, micafungin, or low-dose amphotericin | <5% Respiratory viruses 191 , 193 , 195 , 197 , 198 , 199 , 200 , 201 , 203 … With fluconazole (200 to 400 mg/day), 75 , 76 , 77 voriconazole, 78 or micafungin 79 (50 mg IV once daily) prophylaxis, Candida albicans infections have been mostly eliminated during this risk period; however, Candida krusei and Candida glabrata have emerged as fluconazole-resistant pathogens. 80 Some …

9th Trends in Medical Mycology Held on 11-14 October 2019, Nice, France, Organized under the Auspices of EORTC-IDG and ECMM.

Dear Friends and Colleagues,It is a great honor and pleasure for us to invite you cordially to participate in the 9th Congress on Trends in Medical Mycology (TIMM-9) [...].

Совпадение в полном тексте источника
… on Systematic Fungal Screening Using Galactomannan Antigen, Aspergillus qPCR and Mucorales qPCR | | Anne-Pauline Bellanger, France Symposium 7 | | Paediatric Mycology (EPMyN) | | Chairs: Emmanuel Roilides, FECMM, Greece & Roger Brüggemann, FECMM, The Netherlands 14:15 | S07.1 | Fluconazole and Micafungin … Four (4) out of 6 patients had received prophylactic treatment with antifungal agents (2/4 patients received micafungin and 2/4 l -Amphotericin B). Therapeutically, all patients received l -Amphotericin B ( l -AmB) (median dose: 7.5mg/kg, range: 3-10 mg/kg). …